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Most of you will remember Ian Kennedy's Reith Lectures in 1980 which brought into question the motivations of the medical profession (Kennedy 1981) . He claimed that many of the objectives of the medical profession were alien to the community and that the ambitions of the profession were more self-interested than altruistic. Fulder & Monro (1981) later published the results of their research which showed clearly the demand for alternative therapies. And in 1983 the media took up the cause of alternative medicine against the orthodox profession. They claimed that Britain's doctors were biased towards curative management while holistic forms of therapy were in demand. Much publicity was given to the opening of new centres of holistic medicine for the treatment of patients with cancer. The suggestion was clearly that conventional medicine had failed these patients and that alternative therapies had something to offer.
In September 1983 the first Annual Meeting of the recently formed British Association of Holistic Medicine was held. The journalists Ruth West and Brian Inglis wrote a series of articles in The Times (1983) on the subject of holistic medicine entitled 'Time to Shake the Medicine', in which they suggested that doctors should perhaps provide these alternative therapies themselves. They advised that adequate and proper training would have to be introduced.
But here traditional medicine has a major problem. Most of these so-called alternative therapies have no proven value, although it must be conceded that others such as chiropraxy have been shown to produce impressive results. The development of modern medicine depends on the scientific evaluation of innovations in management. Such evaluation requires objective assessment in controlled trials designed to refute the possible benefit of the experimental treatment. Properly designed clinical trials are not promoted to demonstrate that the new treatment is better than the standard management. The scientific principle of their design and their ethical justification should be that there is no real difference (Popper 1963 ). On the other hand, not only is there no sound basis for most so-called alternative therapies, but if they are offered with all sorts of ill-defined possible benefits it may be difficult to determine exactly what is claimed of them. In cancer therapy, holistic medicine has been found to be particularly attractive to patients who are terminally ill or who are suffering severe morbidity from various forms of anticancer treatment. Holistic medicine for the cancer patient offers caring and general support rather than specific treatment and any hope of curing the disease. But this is often exactly what patients require and would choose when realistically there is no probability of cure. It must be recognized that doctors may be less willing to face reality than their patients. It then has to be accepted that oncologists have been too concerned with survival;
that the pursuit of cure has obscured the need equally to care. There seems little doubt that doctors do tend to take more risks in management than would their patients if they were provided with the information on which to make a reasonable decision. In the war against cancer, doctors as a profession are too often prepared to try to win every battle, but as individuals we know that it is not what every patient wants.
Philip Rubin (1983) , a leading North American oncologist, has stated in a widely read manual of cancer therapy that 'As the chance for cure decreases, the tendency to be more radical appears justified. In many circumstances that may not be a decision that will allow a successful result. A conservative approach may lead to a recurrence, whereas a more radical attack may lead to an increased mortality. As in many problems in medicine, the choice is relative. What percentage of survival is acceptable for a debilitating therapeutic modality, be it surgery, radiotherapy or chemotherapy? There is no formula or figure other than personal perspective'.
But whose perspective? That advice is given to the physician so that he might choose what appears to be the best management in his or her experience. My argument would be that patients will have some personal perspective on the subject. We have to accept that 'consumer or client groups' are now quite prepared to make choices about their management and many are sufficiently well informed to be rightly critical of the decisions made by doctors. Many doctors deceive themselves in believing that patients require to be protected from decisionmaking. Some patients do, but the majority are capable of making a free and rational choice given proper clinical advice. The decision may not, of course, coincide with that of the oncologist but that does not make it wrong. We live in rapidly changing and challenging times and doctors are now increasingly required to offer choices, not make them.
The caring option is more demanding clinically and emotionally as it requires a continuing commitment to total care, the holistic philosophy, and to the ever-changing needs of a patient. It requires a flexibility in approach to keep reassessing and redefining the objectives of management, as the disease progresses often at an uneven or capricious pace. Responsibility for patient care may have to be passed from one doctor to another as the illness progresses. There is no place for the traditional British practice of 'sovereignty for patient care' whereby the clinician to whom the patient was first referred retains permanent responsibility for all management decisions. No one specialist has all the knowledge or skills that may be needed during the course of the disease. But this does pose problems and introduces strains in interprofessional relationships. And it must be clear to patients to whom they should relate for specialist advice at any one time in addition to their GP.
Curative treatment, on the other hand, requires a single decision about definitive management, after which many doctors may have little interest. That aggressive approach is a source of tension initially between doctor and patient and at times may be followed by a sense of failure in the doctor and a sense of abandonment in the patient. Ian Kennedy (1981) in his Reith Lectures charged that 'Doctors, for the most part will opt out of devoting themselves to people who offer no obvious reward, no prospect of achieving something by way of cure'. It is then that patients understandably turn to alternative therapies for support. But curative treatment must be associated with caring just as much as palliative management. Indeed, that caring should be demonstrated initially by involving the patient in decision-making. Obviously the cornerstone of decision-making of this kind is a well conducted audit of the outcome of management, including survival and patterns of failure.
We have to realize that it is now equally important to measure the morbidity of management as objectively as possible ( Figure 1 ). Lord Kelvin stated 'When you can measure what you are speaking of and express it in terms of numbers you know something about it: when you cannot express it in terms of numbers your knowledge of it is of a meagre kind'. It is now very important that oncologists regularly score numerically the complications of treatment including the psychological sequelae they observe. There are several satisfactory systems of scoring morbidity that quantify the severity of complications which may be recorded in clinical practice. They have at the moment very obvious deficiencies but improvements will only come from their more general use, which is presently confined to academic centres. Even there, they are usually applied only in the context of clinical trials. These non-parametric scoring systems measure the severity of complications, and there are now techniques which can transform these data and test their statistical significance. One example only need be given. Radiotherapy is commonly used as the primary treatment of patients with cancer of the uterine cervix. The probability of achieving local tumour control decreases as the stage of advancement increases and treatment will tend to be more aggressive (Hanks 1981) . As a result the incidence of severe radiation-related morbidity will increase, as illustrated in Figure  2 . The justification for this approach depends on improved survival rates in patients with cervical cancer. In treating other cancers, increased morbidity may be associated with a higher mortality and difficulties in decision-making about optimum management.
The measurement of quality of life has presented even greater problems to physicians. Most oncologists make some use of the Karnofsky Performance Index, but this is a very crude and grossly inadequate scoring system (Karnofsky & Burchanal 1948) . Grogono & Woodgate (1971) introduced a more comprehensive scheme of measuring the quality of life (Table 1) . The scheme examines ten functional activities and uses a simple three-point numerical score based on the clinical assessment: being considered normal = 1, impaired = 1/2 or incapacitated = 0. These assessments can be made quite easily with the help of a structured questionnaire which may be completed by interrogation of the patient or by self-assessment. Jt does require additional time, but if regularly used should take at most five minutes for each patient with the help of a nurse. These systems are being improved and perfected (Priestman & Baum 1976 , Spitzer et al. 1981 .
It is necessary to make a value judgment about the relative importance of good quality of life and its duration. The two examples illustrated in Figure 3 might be assessed as equivalent by measuring the area under the two curves. When one considers the emphasis placed on the importance of survival in the medical literaturecrude survival, disease-free survival, actuarial survival, and so onit is likely that physicians and surgeons would choose treatment 'B' which gives the longer survival, regardless of the time-scale. But I would suggest that most patients would choose treatment 'A' for both long and short time-scales. It may in special circumstances be important for certain patients to achieve the longest possible survival, even with the necessity to accept a progressive deterioration in the quality of life over that time, and that of course has to be taken into consideration in decision-making.
Some progress has been made in the treatment of small-cell cancer of the lung by the use of cytotoxic drugs. An increase in median survival of about 5 months may be achieved at the cost of 8 months' cytotoxic chemotherapy ( Figure 4 ). But when compared with radiotherapy alone (MRC 1981) the question must be asked, 'Did the quality of life during that period justify treatment with these drugs?'TI remember very well as a young doctor, when giving a seminar on cancer management to a Pastoral Care Course, being asked by an equally young cleric, 'Tell me doctor, do you regard every death as a failure?' Moliere put it well when he wrote 'Life is not an end in itself but what use we make of it'. Recently in the USA a President's Commission (1983) extended its original remit to publish its views on the withholding and stopping of treatment. It was considered proper that most patients should decide for themselves what treatment would be accepted or refused, even if that might lead to earlier death. But the choice of management involves many straightforward questions of direct concern to the patient. How effective is treatment? What are its hazards? Are they acceptable? The subject of the management of breast cancer may be taken as an example of some of the principles that have to be considered. For many years the standard operation has been the Halsted or radical mastectomy. Because of its morbidity in terms of physical disability, many surgeons have adopted a modified or Patey mastectomy which is associated with less arm swelling and less impairment of shoulder movement. Mastectomy, however, is also associated with considerable psychological morbidity. Maguire in Manchester has observed that one-quarter of patients after mastectomy may need treatment for anxiety or depression and one-third may have marital problems or serious sexual difficulties (Maguire et al. 1978) . In Edinburgh, Dean compared womens' self-assessment of their body image after mastectomy and after silastic implant (Dean et al. 1983) (Table 2) . A significantly higher proportion of patients who had mastectomy alone considered that they felt mutilated. The early implantation of a silastic prosthesis significantly reduces this mental and physical trauma, but it is now clear that in most patients with operable breast cancer mastectomy offers no advantage either in relation to survival or to local control of the cancer. Veronesi & Costa (1982) have demonstrated that limited excision of the lump and axillary clearance followed by radiotherapy is as good as a Halsted mastectomy for patients with early breast cancer ( Figure 5 ). Indeed, in patients with histologically involved axillary nodes the survival is significantly better after quadrantectomy, axillary dissection and radiotherapy. It is now unnecessary in the majority of women to perform mastectomy unless that is their choice. Conservative management gives equally good tumour control and survival. The need to perform breast reconstruction is hardly relevant! However, if a woman should choose to have a mastectomy the option should include the offer of a silastic implant or breast reconstruction. I believe most women will welcome the fact that mastectomy is no longer an essential part of the management of breast cancer, and avoiding breast amputation should produce a reduction in the psychiatric morbidity and other problems commonly observed after mastectomy. I would hope, too, that the effectiveness of conservative management may encourage women with breast cancer to present earlier, for there are many who at present conceal their disease for too long because of the fear of the mutilating effects of management ( Figure 6 ). It is known that women who are aware of a lump in the breast delay longer if they think it is cancer than if they consider it to be a benign cyst or inflammatory disease.
Another clinical problem which continues to give rise to controversy in the management of breast cancer is the routine use of adjuvant cytotoxic chemotherapy. The rationalists would argue that since many patients with early breast cancer will have occult metastatic disease, all should be given cytotoxic chemotherapy. The empiricists have carried out many randomly controlled studies and there is no consistent evidence that there is any beneficial effect other than an increase in disease-free survival in a particular subgroup of patients. It is, however, possible to examine the treatment options by decision theory in terms of what are called 'utility functions'. Table 3 illustrates the calculation of a utility score for patients with Stage I and Stage II breast cancer managed without cytotoxic chemotherapy. The data of probabilities are based on a large series of patients with operable breast cancer treated in Edinburgh between 1960 and 1975 (Langlands et al. 1982 . Events are then given a score ranging from 5 (perfect result) to 0 when death results. The total utility score following a 'watch' policy is 2.4. This assessment may be compared with the 'utility' of an adjuvant chemotherapy programme based on data from reported trials. The disease-free survival is improved a little, but because of the morbidity associated with the drug therapy which has to be given to all patients, the 'utility' score has been slightly reduced (Table 4 ). In terms of these utilities, adjuvant chemotherapy has nothing to commend it as a rational policy for all patients, but when patients with heavy involvement of axillary lymph nodes by disease are included a slight benefit in utility might be observed. This score does depend very much on the regimen of cytotoxic chemotherapy employed, for treatment toxicity varies greatly with different drug schedules. The most commonly used regimen, known as CMF, includes the drugs cyclophosphamide, methotrexate and 5-fluorouracil, and in one British Study 79% of patients had side effects which seriously interfered with their normal life style (Palmer et al. 1980) . Twenty-nine percent found the drugs so toxic that they stated that they would not go through the experience again. Similar findings have been reported from the USA and, more importantly, about one-third of patients may refuse to persist with drug treatment (Wilcox et al. 1982) . In addition, the psychiatric morbidity referred to earlier is much greater in patients treated with this CMF regimen (Maguire et al. 1980 , Brinkley 1983 ).
The rationalists have introduced a treatment which adds much physical and emotional trauma to these patients with breast cancer, for little or no benefit in survival. Their arguments remain a powerful influence in determining the choice of treatment made by physicians and surgeons in spite of the empirical findings from randomized clinical trials.
A slightly different problem where decision theory may be applied has occurred in the debate on the optimum management of patients with Stage I teratoma testis. It is accepted that the primary management of choice is orchidectomy and it is known that about 20% of these patients will develop spread to the retroperitoneal lymph nodes and/or the lungs.
In the UK the orthodox management has been to irradiate the abdominal lymph nodes along the recognized routes of lymphatic spread. In the USA the practice is usually to perform retroperitoneal lymphadenectomy. It has to be conceded, therefore, that at least 80% of patients in this stage category are being given adjuvant treatment unnecessarily. It is, however, effective in that 95% of patients will be cured of their disease. On the other hand, it has to be argued that since there is now effective cytotoxic chemotherapy for this form of cancer, it may no longer be justified to treat patients routinely by surgery or radiotherapy. It has been proposed that these patients should be kept under very close surveillance by clinical examination, regular CT scans and follow-up lymphograms and by assay of tumour markers in the peripheral blood (Peckham et al. 1982) . The cost of these procedures and their administrative control are considerable, and certainly have to be accounted for at some point. However, if that consideration ofcost may be ignored, it is possible to consider the advantages of the two approaches by decision-making theory. The data are taken from series of patients who have been routinely treated -by adjuvant radiotherapy in Edinburgh (Munro & Duncan 1985) and a small experimental study of the surveillance policy followed at the Royal Marsden Hospital (Peckham et al. 1982) . It can be seen from Table 5 that 'routine radiotherapy' will achieve a 78% five-year survival with negligible morbidity which is accorded a score of 4. Twenty-two percent of patients will have varying degrees of morbidity, which takes account of the fact that 16% of these patients will require cytotoxic chemotherapy. The total utility for the policy of management is 3.54. The surveillance policy may then be compared (Table 6 ) and the total utility may be assessed to be 3.4; by this analysis there is little difference frQm the policy of 'routine radiotherapy'. It is assumed that 75% will not relapse and so will be given no further treatment. Twenty-five percent will relapse and will be given cytotoxic chemotherapy, resulting in complete regression of tumour but with appreciable morbidity. This example from current clinical practice illustrates just how inadequate is survival experience alone in assessing the quality of patient care. Even if the surveillance policy was assessed to be perfect, imposing no inconvenience, loss of earnings or added anxiety to the patient and a score of 5 awarded, the relapse-free rate would also have to be in excess of 80% before the total utility score was greater than that of a policy of routine primary radiotherapy and secondary cytotoxic chemotherapy for the few who relapse.
Carcinoma of the rectum is one of the commonest cancers associated with Western life style. In the United Kingdom the more usual treatment is abdominoperineal excision with the formation of a colostomy. About 75% of patients are managed in this way, while the remainder have anterior restoration resection which restores the continuity of the bowel immediately following removal of the cancer. Current management in this country is hardly conducive to Western-style living. A recent study of Williams & Johnston (1983) has shown how great is the morbidity associated with abdominoperineal excision (Table 7) . Only 40% of these patients returned to work after operation, almost one-third had impaired sexual function and none was continent. The morbidity associated with a sphincter-conserving operation is much less severe, the difference being highly significant statistically. In addition, many of these patients suffer quite serious psychiatric disturbances after major operations of this kind (Table 8) . Depressive illness was significantly less common in patients after anterior restorative operations compared with abdominoperoneal excision, and loss of self respect was also significantly less. The fear of the surgeon is that the probability of local recurrence may be greater after anterior restorative operations, but it would seem reasonable to seek the patients' views about how important that risk is when measured against being continent, retaining self confidence and being able to return to full employment. McNeil and her colleagues (1978) have obtained responses from simulated patients with lung cancer who were able to weigh the probability of surviving three years after operation against rates of operation mortality from 5 to 25%. The technique requires patient groups to gamble on their probability of long or short survival. The results indicate that patients would not be prepared to take as much risk as their surgeons. They are more interested in caring rather than in curing. Responses have not been sought on the subject of radical excision for cancer of the oesophagus, but when one considers the extremely poor five-year survival rate of no more than 9% and an operative mortality rate of about 15%, I wonder if many patients would choose operation rather than radiotherapy which offers similar survival rates, has negligible associated mortality, and is only marginally less effective in the relief of symptoms. McNeil et al. (1981) have also illustrated that client groups will be prepared to make decisive choices about the management of locally advanced cancer of the larynx. These groups were given the information that laryngectomy would offer a 60% probability of 5-year survival at a cost of losing the voice-box. Radiotherapy might not be as successful but would allow a normal voice to be retained. They were given the opportunity to listen to tapes of a very good performer of oesophageal speech and of an average performer before being asked to make their choice of treatment. When the difference in survival results was 30% all elected to have a laryngectomy, but interestingly when results of surgery were only 20% better than radiotherapy about one-quarter of patients would choose not to have surgery and an artificial voice. If one assumes that the majority of patients would choose primary radiotherapy if there was no difference in survival experience, then I think the slope of regression is very steep indeed (Figure 7 ). Patients will very decisively influence treatment policy if given the necessary information and the opportunity to make a choice. Of course, other factors such as age and performance status are vitally -important in decision-making and have to be taken into account.
Significant improvement in survival of patients with deeply invasive bladder cancer has been demonstrated following preoperative X-ray therapy plus cystectomy compared with the results of radical radiotherapy above (Figure 8) (Bloom 1981) . How important is that increased survival (of 9% at 5 years) without a normal bladder? The results of this excellent trial would have had more significance if morbidity and particularly the quality of life had also been assessed. Surgeons and patients should know how many patients felt fitter, more confident and more able to enjoy their usual life style following cystectomy than following radiotherapy alone. But these important facts are not available to help in decision-making in the future. The unconvinced may simply rearrange their prejudices and continue to choose whatever treatment option they feel is best. 
Conclusions
Doctors have been too much concerned with cure and the pursuit of prolongation of life.
Oncologists have to become more interested in the quality of life following treatment and be more responsive to patients' opinions about the choice of management. Doctors have to realize that increasingly they will be expected to offer choices, not make them, when treatment options are discussed. We must be more prepared to define the objectives of management, in consultation with our patients, and redefine them as time progresses.
Oncologists have to be more committed to a critical audit of the outcome of management, particularly the patterns of failure, as well as measuring the probabilities of success in eradicating the disease. We have to become more dedicated to the objective measurement of the morbidity of management, taking account of the subjective evaluation of our patients.
We must be more appreciative of the need to determine accurate indices of the quality of life of our patients and learn to respect their importance in determining treatment strategies. I can foresee the day when medical ethics committees will require that the protocol of every therapeutic trial includes a quantitative assessment of treatment-related complications and of the ensuing quality of life. Their evaluation may commonly be the decisive factor in comparing different treatments, certainly as far as the patient is concerned! Clinical oncology, like all branches of modern medicine, is concerned with 'the art of the probable'. The measurement of probabilities, of local recurrence of cancer, of distant spread, and particularly of morbidity and the quality of life after different forms of management is now an essential element of clinical science. We have to .learn, and our studentsundergraduate and postgraduate -have to be taught how to use these new techniques of measurement and about the new methods of their statistical analysis and evaluation. The 'art' of medicine is to combine the scientific approach with the traditional qualities of a caring and compassionate profession. It is ironic that the financial constraints being imposed on the Health Service may require doctors to take more decisions about management which will be more respectful of their patients rather than of themselves and their professional peers.
